MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s13277-015-4153-0

Медицинская библиотека · Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015

The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study.

Li Qing, Peng Yu, Wang Lin-Ang, Wei Xi, Li Meng-Xia, Qing Yi, Xia Wei, Cheng Ming, Zi Dan, Li Chun-Xue, Wang Dong

СтатьяПеревод в очереди

Аннотация

Rectal cancer, defined as a cancerous lesion of the colon distal to the rectosigmoid junction, is the fourth most common cancer cause of death globally. There were 474 patients with rectal cancer who underwent surgery between October 2007 and May 2013 enrolled in our center. Patients were respectively categorized by neoadjuvant therapy. This study aimed to explore the predictive factors that affected the Progression-free survival and overall survival of the patients with rectal cancer. Clinical characteristics of patients were compared with the groups and potential prognostic factors were analyzed by SPSS 19.0. In our study, neoadjuvant therapy increased the anus-retained rate (64.4 vs 53.4 % P = 0.016) and remission rate in the treatment group, compared to the non-treatment group (62.6 vs 34.8 %; P = 0.000). The neoadjuvant concurrent chemoradiotherapy, more operative duration, anus retained and micturition damaged are positive prognostic factors of PFS to patients. Poor differentiation, the tumor of ulcer, invasive, and pT4 stage, contributed the poor factors for PFS of patients (P < 0.05). Additionally, the patients with neoadjuvant concurrent chemoradiotherapy and adjuvant chemotherapy underwent the better prognosis of OS. Adjuvant chemotherapy cannot increase PFS of the patients who accepted neoadjuvant therapy after surgery get pCR, but can improve OS. The anus-retained and neoadjuvant radiotherapy, duration of surgery in rectal cancer have the positive correlation. Micturition damaged and neoadjuvant radiotherapy were positively correlated as well. In conclusion, adjuvant chemotherapy does not improve the PFS of patients with pCR to neoadjuvant therapy, but is good for OS. Further prospective and large population-based clinical studies are needed to establish clinical guidelines for the use of neoadjuvant therapy and adjuvant chemotherapy in patients with rectal cancer.

Для цитирования: Li Qing, Peng Yu, Wang Lin-Ang, Wei Xi, Li Meng-Xia, Qing Yi, Xia Wei, Cheng Ming, Zi Dan, Li Chun-Xue, Wang Dong. The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study.. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. DOI: 10.1007/s13277-015-4153-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.